eMedicine Specialties > Dermatology > Diseases of the Oral Mucosa
Oral Hemangiomas
Updated: Nov 12, 2008
Introduction
Background
Hemangiomas are tumors identified by rapid endothelial cell proliferation in early infancy, followed by involution over time; all other abnormalities are malformations resulting from anomalous development of vascular plexuses. The malformations have a normal endothelial cell growth cycle that affects the veins, the capillaries, or the lymphatics, and they do not involute.
Hemangiomas are lesions that are not present at birth. They manifest within the first month of life, exhibit a rapid proliferative phase, and slowly involute to near complete resolution. Hemangiomas exhibit both a proliferating phase and an involuting phase, whereas vascular malformations are more stable and fail to regress.1
Hemangiomas of the oral cavity are not common pathologic entities, but, among hemangiomas, the head and the neck are common sites. Most true hemangiomas involute with time, but a certain small percentage do not, which may present with complications that require treatment (see Complications). An estimated 10-20% of true hemangiomas incompletely involute and require postadolescent ablative treatment.2
Hemangiomas are associated with the following syndromes:
- Rendu-Osler-Weber syndrome (autosomal dominant inheritance, multiple telangiectasias, occasional GI tract involvement, occasional CNS involvement)
- Sturge-Weber-Dimitri syndrome (noninherited and nonfamilial, port-wine stain, leptomeningeal angiomas)
- Kasabach-Merritt syndrome (thrombocytopenic purpura associated with hemangioma, consumptive coagulopathy, microangiopathic hemolysis, intralesional fibrinolysis)
- Maffucci syndrome (hemangiomas of the mucous membranes, dyschondroplasia)
- von Hippel-Lindau syndrome (genetic transmission variable, hemangiomas of the cerebellum or the retina, cysts of the viscera)
- Klippel-Trenaunay-Weber syndrome (port-wine stain, angiomatosis of the extremities)
- PHACE(S) (posterior fossa brain malformations, hemangiomas of the face [large or complex], arterial anomalies, cardiac anomalies, and eye abnormalities): The association is referred to as PHACE(S) when ventral developmental defects, such as sternal clefting or supraumbilical raphe, are present.
The term hemangioma has been commonly used to describe a large number of vasoformative tumors. Unfortunately, the nomenclature and the classification of these entities have been complex and not entirely consistent over time. The complexity and the inconsistency have led to a large number of terms and classification schemes being used, resulting in confusion in understanding the pathophysiology of these lesions and in comparing data from different periods. The nomenclature lends little insight into the natural history and the management of these lesions.
What was referred to as a hemangioma 30 years ago is not necessarily what a hemangioma would be referred to as today. The term hemangioma described many lesions that bore little relationship to each other apart from their being involved with vessels. With this concept in mind, this article discusses oral vasoformative tumors under the broad and not entirely correct term oral hemangiomas.
In 1982, Mulliken and Glowacki1 described the classification scheme that is most accepted today. This scheme is straightforward and essentially divides the vasoformative tumors into 2 broad groups: hemangiomas and vascular malformations (see Table 1 below). The vascular malformations can be further subdivided into arterial, venous, capillary, and lymphatic malformations.
Table 1. Classification of Vasoformative TumorsOpen table in new window
Table
| Vasoformative Tumor | New Nomenclature | Old Nomenclature |
| Hemangiomas | ||
| Capillary hemangioma | Strawberry hemangioma | |
| Juvenile hemangioma | ||
| Cavernous hemangioma | ||
| Mixed hemangioma | Parotid hemangioma | |
| Vascular malformations | ||
| Venous malformation | Cavernous hemangioma | |
| Hemangiomatosis | ||
| Intramuscular venous malformation | Intramuscular hemangioma | |
| Capillary malformation | Capillary hemangioma | |
| Port-wine stain | ||
| Arteriovenous malformation | Arteriovenous hemangioma Arterial angioma Arteriovenous aneurysm Cirsoid angioma Red angioma Serpentine aneurysm | |
| Lymphatic malformation | Capillary lymphangioma Cavernous lymphangioma Lymphangioma Cystic hygroma |
| Vasoformative Tumor | New Nomenclature | Old Nomenclature |
| Hemangiomas | ||
| Capillary hemangioma | Strawberry hemangioma | |
| Juvenile hemangioma | ||
| Cavernous hemangioma | ||
| Mixed hemangioma | Parotid hemangioma | |
| Vascular malformations | ||
| Venous malformation | Cavernous hemangioma | |
| Hemangiomatosis | ||
| Intramuscular venous malformation | Intramuscular hemangioma | |
| Capillary malformation | Capillary hemangioma | |
| Port-wine stain | ||
| Arteriovenous malformation | Arteriovenous hemangioma Arterial angioma Arteriovenous aneurysm Cirsoid angioma Red angioma Serpentine aneurysm | |
| Lymphatic malformation | Capillary lymphangioma Cavernous lymphangioma Lymphangioma Cystic hygroma |
Pathophysiology
Vascular malformations need to be understood in terms of their embryology and development. The classic sequence of events usually falls into 3 stages: (1) the undifferentiated capillary network stage, (2) the retiform developmental stage, and (3) the final developmental stage. In the undifferentiated capillary network stage, the primitive mesenchyme is nourished by an interlacing system of blood spaces without distinguishable arterial and venous channels. Separate venous and arterial stems appear on either side of the capillary network in the retiform developmental stage. The retiform developmental stage begins at about 48 days of embryonic development. The final developmental stage begins at 2 months' development and involves the gradual replacement of the immature plexiform network by the mature vascular channels.
The more common capillary hemangioma represents an arrest in the development of the mesenchyme primordia in the undifferentiated capillary network stage. As differentiation progresses, primitive vessels penetrate deeper into the subcutaneous layer, the muscle, or the bone tissue and give rise to capillary hemangiomas. Termination of development in the retiform developmental stage may produce venous, arterial, or capillary malformations because this stage is characterized by an established venous, arterial, and capillary system. In the final developmental stage, the maturation of the venous and lymphatic systems predominates. Aberrations in this mature stage of development result in venous malformations and lymphangiomas.
Proliferating hemangiomas have been shown to have estradiol-17 beta-receptors in the cytoplasm,3 and corticosteroid treatment has been theorized to block these receptors. Lack of estradiol receptors in stable or involuting lesions has supported this theory, and steroid treatment has become a first line of treatment for proliferating lesions.
A number of growth factors, including vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), transforming growth factor-beta (TGF-beta), and interleukin 6 (IL-6), have been demonstrated as regulators of angiogenesis.4 Takahashi et al5 outlined a number of cellular markers that distinguish the phases of hemangiomas; these markers include tissue metalloproteinase (TIMP-1), bFGF, proliferating cell nuclear antigen, type IV collagenase, VEGF, and urokinase.
Another theory suggests that the endothelial cells of hemangiomas are derived from a distant population of endothelial precursors carried by existing vascular pathways to a receptive environment. Potential sources include the bone marrow and the placenta. A small embolic nidus of placental endothelial cells could reach fetal tissues through the permissive right-to-left fetal shunt of fetal circulation.
This occurrence could, in part, explain the 3-fold increased risk of hemangiomas observed in infants subjected in utero to chorionic villus sampling, because local placental injury might predispose the shedding of cells into the fetal circulation. At least 5 markers of hemangiomas are uniquely co-expressed in the placenta: GLUT1, merosin, Lewis Y antigen, Fc-R11b, and type III iodothyronine deiodinase. Recently, a comparison of the transcriptomes of the human placenta and infantile hemangiomas supported a placental origin of the tumors.6
Frequency
United States
Hemangiomas are the most common tumors of infancy, occurring in as many as 2.6% of neonates and 12% of children aged 1 year.7,8 Up to 30% of preterm infants with low birth weight (1000 g) may have hemangiomas.9 Fifty percent of venous malformations occur in the head and the neck.10
In the oral cavity, the bones and the muscles are affected as well as the mucosa and the skin. The incidence of intraosseous hemangiomas varies from 0.5-1.0% of all intraosseous neoplasms.11 The bones most frequently affected are the vertebral column and the calvaria. The most commonly affected facial bones are the mandible, the maxilla, and the nasal bones. Intraosseous lesions affect the mandible more often than the maxilla, with a ratio of 2:1 reported in one study.12 Involvement of the zygoma is rare.13
Intramuscular hemangiomas in the oral region are most commonly seen in the masseter, compromising 5% of all intramuscular hemangiomas.14
Mortality/Morbidity
The morbidity of oral hemangiomas ranges from surface discoloration to life-threatening functional compromise of the airway or hemorrhage. Fatal spontaneous hemorrhage from jaw hemangiomas has been documented in 25 cases.15 Significant morbidity can also occur from many of the treatments of hemangiomas, and biopsy of these lesions is also fraught with danger.
Race
Hemangioma, the most common tumor of infancy, affects as many as 12% of whites, but it rarely occurs in darker-skinned individuals. Vascular malformations also more commonly occur in whites.
Sex
Hemangiomas are approximately 3-5 times more common in females than in males.16
- The male-to-female ratio for venous malformations is reported in one study10 to be 1:1.
- Arteriovenous hemangiomas of the oral cavity have a predilection for females.17
- Intraosseous hemangiomas are about 3 times more common in females than in males.12,15
- The patient's sex does not influence the speed or the completeness of involution of hemangiomas.18
Age
By their definition, hemangiomas occur in infants and children. The incidence of hemangiomas increases to 23% in premature infants with a birthweight of less than 1000 g.
- Vascular malformations have a much broader range of incidence. Barrett and Speight17 observed 35 oral vascular malformations over a 48-year period at their institution. The mean age was 52.6 years, with a range of 12-90 years.
- Intraosseous vascular malformations most commonly occur in the fourth decade of life but range from infancy to the eighth decade of life.
- The peak incidence of central vascular malformations of the jaws is in the second decade of life.15
- Intramuscular vascular malformation of the head and the neck most commonly present in the third decade of life.14
Clinical
History
Hemangiomas and vascular malformations are diagnosed fairly easily with a careful history and a physical examination.
- Capillary hemangiomas are usually not present at birth but are antedated by a pale, well-demarcated, flat area, most visible with agitation.
- These prodromal lesions may appear as a pale halo surrounding an area of telangiectasis or as a very fine telangiectasia similar to the port-wine stain.
- Elevation occurs early during the first year of life and increases from the ages of 3-8 months, with some growth continuing into the second year of life. A stable interval of 6-12 months often follows the growth period. Then, a slow spontaneous involution, which usually begins in the center of the lesion, takes place in most cases. Involution often begins as a darkening of color followed by the appearance of numerous gray or pallid regions and fibrous septae within the lesion. Historically, most lesions have reportedly involuted by the time the patient is aged 7 years, with 86% of those lesions regressing by the time the patient is aged 5 years.19,20,21,18,22
- The patient's sex and the size of the hemangioma do not influence the speed or the completeness of resolution.
- The location of the lesion does not generally influence its behavior, but lesions of the lower lip are less favorable.
- Patients with multiple lesions have rates of resolution similar to those with single lesions; however, separate lesions in the same individual do not necessarily grow or involute simultaneously. Lesions that have not improved after 3 years are unlikely to resolve by age 7 years. Unfortunately, early improvement does not always lead to early resolution. Involution may continue into the late teenage years.
- Cavernous hemangiomas are composed of large, irregular, deep dermal and subcutaneous blood-filled channels that impart a purplish discoloration to the overlying skin. They are typically soft, poorly defined, and readily blanch with compression, giving them a characteristic "bag of worms" feel.
- The lesion may expand and darken with crying, when agitated, or when placed in a dependent position. Often, a capillary component overlies a cavernous component, and it may be difficult to distinguish these components histologically.
- Cavernous and mixed hemangiomas demonstrate the same patterns of proliferation as those of capillary lesions. However, involution is often incomplete, depending on the location and the presence of associated arteriovenous malformations.
- Vascular malformations are present at birth and continue to grow with the child. The growth may become accelerated when the patient undergoes puberty or pregnancy, with the attendant hormonal changes.
Physical
- On examination of the oral cavity, the vascular malformations of the mucosa and the adjacent soft tissues are usually readily apparent.
- The tissues have a slightly bluish hue and are soft.
- Venous channels become engorged when placed in a dependent position. They are readily compressible and fill slowly when released.
- They lack a prominent pulsation; if they represent an arteriovenous malformation, a thrill may be present.
- Although the mucosal and soft tissue lesions are readily suspected by their appearance, the intrabony lesions may be difficult to distinguish on sight alone.
- Central jaw lesions can show hypermobility of the teeth and distortion of the arch form.12
- Severe hemorrhage following dental extraction is not an uncommon presentation of central hemangiomas of the maxilla and the mandible.15
- Common clinical findings in central hemangiomas of the jaws include gingival bleeding, postextraction bleeding, swelling, pain, mobility of the teeth, and bony expansion.15
- Root resorption of the teeth has been reported in 30% of cases, but the vitality of the teeth is usually not affected.12
- Intramuscular vascular malformations represent a challenge on diagnosis because they exhibit few signs on clinical examination. Oftentimes, the extent of the lesion is not clinically apparent on examination, and imaging studies frequently define more extensive lesions than suspected.
Causes
The causes of vasoformative tumors are unknown. One hypothesis postulates that placental cells, such as the trophoblast, may be the cell of origin for hemangiomas. Therefore, hemangiomas may arise secondary to some event in utero. However, conflicting evidence supports this hypothesis. One study found placenta-associated vascular antigens to be expressed by hemangiomas but not by other vascular malformations or tumors. On the other hand, a separate investigation found immunohistochemical staining of certain trophoblastic markers to be negative in all infantile hemangiomas that were examined. The relationship between hemangiomas and placental tissues needs further investigation.
More on Oral Hemangiomas |
Overview: Oral Hemangiomas |
| Differential Diagnoses & Workup: Oral Hemangiomas |
| Treatment & Medication: Oral Hemangiomas |
| Follow-up: Oral Hemangiomas |
| References |
| Next Page » |
References
Mulliken JB, Glowacki J. Hemangiomas and vascular malformations in infants and children: a classification based on endothelial characteristics. Plast Reconstr Surg. Mar 1982;69(3):412-22. [Medline].
Waner M, Suen JY, Dinehart S. Treatment of hemangiomas of the head and neck. Laryngoscope. Oct 1992;102(10):1123-32. [Medline].
Sasaki GH, Pang CY, Wittliff JL. Pathogenesis and treatment of infant skin strawberry hemangiomas: clinical and in vitro studies of hormonal effects. Plast Reconstr Surg. Mar 1984;73(3):359-70. [Medline].
Folkman J, Klagsbrun M. Angiogenic factors. Science. Jan 23 1987;235(4787):442-7. [Medline].
Takahashi K, Mulliken JB, Kozakewich HP, Rogers RA, Folkman J, Ezekowitz RA. Cellular markers that distinguish the phases of hemangioma during infancy and childhood. J Clin Invest. Jun 1994;93(6):2357-64. [Medline].
Christison-Lagay ER, Fishman SJ. Vascular anomalies. Surg Clin North Am. Apr 2006;86(2):393-425, x. [Medline].
Stal S, Hamilton S, Spira M. Hemangiomas, lymphangiomas, and vascular malformations of the head and neck. Otolaryngol Clin North Am. Nov 1986;19(4):769-96. [Medline].
Jacobs AH, Walton RG. The incidence of birthmarks in the neonate. Pediatrics. Aug 1976;58(2):218-22. [Medline].
Amir J, Metzker A, Krikler R, Reisner SH. Strawberry hemangioma in preterm infants. Pediatr Dermatol. Sep 1986;3(4):331-2. [Medline].
de Lorimier AA. Sclerotherapy for venous malformations. J Pediatr Surg. Feb 1995;30(2):188-93; discussion 194. [Medline].
Dahlin DC, Unni KK. Bone Tumors: General Aspects and Data on 8,542 Cases. Springfield, Ill: Thomas;1986.
Hayward JR. Central cavernous hemangioma of the mandible: report of four cases. J Oral Surg. Jul 1981;39(7):526-32. [Medline].
Cuesta Gil M, Navarro-Vila C. Intraosseous hemangioma of the zygomatic bone. A case report. Int J Oral Maxillofac Surg. Oct 1992;21(5):287-91. [Medline].
Wolf GT, Daniel F, Krause CJ, Kaufman RS. Intramuscular hemangioma of the head and neck. Laryngoscope. Feb 1985;95(2):210-3. [Medline].
Yih WY, Ma GS, Merrill RG, Sperry DW. Central hemangioma of the jaws. J Oral Maxillofac Surg. Nov 1989;47(11):1154-60. [Medline].
Marchuk DA. Pathogenesis of hemangioma. J Clin Invest. Mar 2001;107(6):665-6. [Medline].
Barrett AW, Speight PM. Superficial arteriovenous hemangioma of the oral cavity. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. Dec 2000;90(6):731-8. [Medline].
Bowers RE, Graham EA, Tomlinson KM. The natural history of the strawberry nevus. Arch Dermatol. 1960;82:667-680.
Lister WA. The natural history of strawberry nevi. Lancet. 1938;1:1429-1434.
Bivings L. Spontaneous regression of angiomas in children; twenty-two years' observation covering 236 cases. J Pediatr. Dec 1954;45(6):643-7. [Medline].
Blackfield HM, Morris WJ, Torrey FA. Visible hemangiomas: a preliminary statistical report of a 10-year study. Plast Reconstr Surg. 1960;26:326-329.
Grabb WC, Dingman RO, Oneal RM, Dempsey PD. Facial hamartomas in children: neurofibroma, lymphangioma, and hemangioma. Plast Reconstr Surg. Oct 1980;66(4):509-27. [Medline].
Yonetsu K, Nakayama E, Kawazu T, Kanda S, Ozeki S, Shinohara M. Value of contrast-enhanced magnetic resonance imaging in differentiation of hemangiomas from lymphangiomas in the oral and maxillofacial region. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. Oct 1999;88(4):496-500. [Medline].
Johann AC, Salla JT, Gomez RS, de Aguiar MC, Gontijo B, Mesquita RA. GLUT-1 in oral benign vascular lesions. Oral Dis. Jan 2007;13(1):51-5. [Medline].
Kane WJ, Morris S, Jackson IT, et al. Significant hemangiomas and vascular malformations of the head and neck: clinical management and treatment outcomes. Ann Plast Surg. Aug 1995;35(2):133-43. [Medline].
Mulliken JB, Boon LM, Takahashi K, et al. Pharmacologic therapy for endangering hemangiomas. Curr Opin Dermatol. 1995;109-113.
Herrero Hernández A, Escobosa Sánchez O, Acha García T. Successful treatment with vincristine in PHACES syndrome. Clin Transl Oncol. April 2007;9(4):262-3. [Medline].
Fost NC, Esterly NB. Successful treatment of juvenile hemangiomas with prednisone. J Pediatr. Mar 1968;72(3):351-7. [Medline].
Edgerton MT. The treatment of hemangiomas: with special reference to the role of steroid therapy. Ann Surg. May 1976;183(5):517-32. [Medline].
Pope E, Krafchik BR, Macarthur C, Stempak D, Stephens D, Weinstein M, et al. Oral versus high-dose pulse corticosteroids for problematic infantile hemangiomas: a randomized, controlled trial. Pediatrics (Epub). May 2007;119(6):e1239-47. [Medline].
Bartoshesky LE, Bull M, Feingold M. Corticosteroid treatment of cutaneous hemangiomas: how effective? A report on 24 children. Clin Pediatr (Phila). Aug 1978;17(8):625, 629-38. [Medline].
Hawkins DB, Crockett DM, Kahlstrom EJ, MacLaughlin EF. Corticosteroid management of airway hemangiomas: long-term follow-up. Laryngoscope. May 1984;94(5 Pt 1):633-7. [Medline].
Hasan Q, Tan ST, Gush J, Peters SG, Davis PF. Steroid therapy of a proliferating hemangioma: histochemical and molecular changes. Pediatrics. Jan 2000;105(1 Pt 1):117-20. [Medline].
Blei F, Isakoff M, Deb G. The response of parotid hemangiomas to the use of systemic interferon alfa-2a or corticosteroids. Arch Otolaryngol Head Neck Surg. Aug 1997;123(8):841-4. [Medline].
Greinwald JH, Burke DK, Bonthius DJ, Bauman NM, Smith RJ. An update on the treatment of hemangiomas in children with interferon alfa-2a. Arch Otolaryngol Head Neck Surg. Jan 1999;125(1):21-7. [Medline].
Barlow CF, Priebe CJ, Mulliken JB, Barnes PD, Mac Donald D, Folkman J. Spastic diplegia as a complication of interferon Alfa-2a treatment of hemangiomas of infancy. J Pediatr. Mar 1998;132(3 Pt 1):527-30. [Medline].
Berenstein A, Lasjaunias P, Kricheff II. Functional anatomy of the facial vasculature in pathologic conditions and its therapeutic application. AJNR Am J Neuroradiol. Mar-Apr 1983;4(2):149-53. [Medline].
Muto T, Kinehara M, Takahara M, Sato K. Therapeutic embolization of oral hemangiomas with absolute ethanol. J Oral Maxillofac Surg. Jan 1990;48(1):85-8. [Medline].
Gilbert LD, Bakos LH, Graves RW. Sodium morrhuate--an alternative in the treatment of soft tissue hemangiomas. Review of the literature and case reports. W V Dent J. Apr 1981;55(2):11-5. [Medline].
Chin DC. Treatment of maxillary hemangioma with a sclerosing agent. Oral Surg Oral Med Oral Pathol. Mar 1983;55(3):247-9. [Medline].
O'Donovan JC, Donaldson JS, Morello FP, Pensler JM, Vogelzang RL, Bauer B. Symptomatic hemangiomas and venous malformations in infants, children, and young adults: treatment with percutaneous injection of sodium tetradecyl sulfate. AJR Am J Roentgenol. Sep 1997;169(3):723-9. [Medline].
Baurmash H, Mandel L. The nonsurgical treatment of hemangioma with Sotradecol. Oral Surg Oral Med Oral Pathol. Jul 1963;16:777-82. [Medline].
Minkow B, Laufer D, Gutman D. Treatment of oral hemangiomas with local sclerosing agents. Int J Oral Surg. Feb 1979;8(1):18-21. [Medline].
Govrin-Yehudain J, Moscona AR, Calderon N, Hirshowitz B. Treatment of hemangiomas by sclerosing agents: an experimental and clinical study. Ann Plast Surg. Jun 1987;18(6):465-9. [Medline].
Baurmash H, DeChiara S. A conservative approach to the management of orofacial vascular lesions in infants and children: report of cases. J Oral Maxillofac Surg. Nov 1991;49(11):1222-5. [Medline].
Seccia A, Salgarello M. Treatment of angiomas with sclerosing injection of hydroxypolyethoxydodecan. Angiology. Jan 1991;42(1):23-9. [Medline].
Glassberg E, Lask G, Rabinowitz LG, Tunnessen WW Jr. Capillary hemangiomas: case study of a novel laser treatment and a review of therapeutic options. J Dermatol Surg Oncol. Nov 1989;15(11):1214-23. [Medline].
Apfelberg DB. Intralesional laser photocoagulation-steroids as an adjunct to surgery for massive hemangiomas and vascular malformations. Ann Plast Surg. Aug 1995;35(2):144-8; discussion 149. [Medline].
Suen JY, Waner M. Treatment of oral cavity vascular malformations using the neodymium:YAG laser. Arch Otolaryngol Head Neck Surg. Nov 1989;115(11):1329-33. [Medline].
Dixon JA, Davis RK, Gilbertson JJ. Laser photocoagulation of vascular malformations of the tongue. Laryngoscope. May 1986;96(5):537-41. [Medline].
Goldwyn RM, Rosoff CB. Cryosurgery for large hemangiomas in adults. Plast Reconstr Surg. Jun 1969;43(6):605-11. [Medline].
Murphy JB. The management of a large hemangioma of the oral cavity with cryotherapy. J Oral Med. Jul-Sep 1978;33(3):104-6. [Medline].
Gongloff RK. Treatment of intraoral hemangiomas with nitrous oxide cryosurgery. Oral Surg Oral Med Oral Pathol. Jul 1983;56(1):20-4. [Medline].
Hartmann PK, Verne D, Davis RG. Cryosurgical removal of a large oral hemangioma. Oral Surg Oral Med Oral Pathol. Sep 1984;58(3):280-2. [Medline].
Greene LA, Freedman PD, Friedman JM, Wolf M. Capillary hemangioma of the maxilla. A report of two cases in which angiography and embolization were used. Oral Surg Oral Med Oral Pathol. Sep 1990;70(3):268-73. [Medline].
Apfelberg DB, Maser MR, Lash H, White DN. Benefits of the CO2 laser in oral hemangioma excision. Plast Reconstr Surg. Jan 1985;75(1):46-50. [Medline].
Bartlett JA, Riding KH, Salkeld LJ. Management of hemangiomas of the head and neck in children. J Otolaryngol. Apr 1988;17(2):111-20. [Medline].
Boon LM, MacDonald DM, Mulliken JB. Complications of systemic corticosteroid therapy for problematic hemangioma. Plast Reconstr Surg. Nov 1999;104(6):1616-23. [Medline].
Modlin JJ. Capillary hemangiomas of the skin. Surgery. Jul 1955;38(1):169-80. [Medline].
Morgan JF, Schow CE Jr. Use of sodium morrhuate in the management of hemangiomas. J Oral Surg. May 1974;32(5):363-6. [Medline].
Further Reading
Keywords
oral vasoformative tumor, arterial malformation, capillary malformation, lymphatic malformation, vascular malformation, venous malformation, intraosseous hemangioma, intramuscular hemangioma, jaw hemangioma, arteriovenous hemangioma, capillary hemangioma, cavernous hemangioma, mixed hemangioma, strawberry hemangioma, juvenile hemangioma, parotid hemangioma, hemangiomatosis, port-wine stain
Overview: Oral Hemangiomas